Quantification of nuclear 53BP1 foci demonstrated elevated numbers in non-TNBC versus TNBC cells before Eribulin treatment (1.8-fold) and Eribulin-induced foci accumulation in both breast cancer cell types (1.5- to 2.0-fold) (Supplementary Figure S3). Here, TP53BP1 is linked to breast cancer.